Literature DB >> 25414666

Feasibility of the Medial Temporal lobe Atrophy index (MTAi) and derived methods for measuring atrophy of the medial temporal lobe.

Francisco Conejo Bayón1, Jesús Maese2, Aníbal Fernandez Oliveira1, Tamara Mesas1, Estibaliz Herrera de la Llave1, Tania Alvarez Avellón3, Manuel Menéndez-González4.   

Abstract

INTRODUCTION: The Medial Temporal-lobe Atrophy index (MTAi), 2D-Medial Temporal Atrophy (2D-MTA), yearly rate of MTA (yrRMTA) and yearly rate of relative MTA (yrRMTA) are simple protocols for measuring the relative extent of atrophy in the medial temporal lobe (MTL) in relation to the global brain atrophy. Albeit preliminary studies showed interest of these methods in the diagnosis of Alzheimer's disease (AD), frontotemporal lobe degeneration (FTLD) and correlation with cognitive impairment in Parkinson's disease (PD), formal feasibility and validity studies remained pending. As a first step, we aimed to assess the feasibility. Mainly, we aimed to assess the reproducibility of measuring the areas needed to compute these indices. We also aimed to assess the efforts needed to start using these methods correctly.
METHODS: A series of 290 1.5T-MRI studies from 230 subjects ranging 65-85 years old who had been studied for cognitive impairment were used in this study. Six inexperienced tracers (IT) plus one experienced tracer (ET) traced the three areas needed to compute the indices. Finally, tracers underwent a short survey on their experience learning to compute the MTAi and experience of usage, including items relative to training time needed to understand and apply the MTAi, time to perform a study after training and overall satisfaction.
RESULTS: Learning to trace the areas needed to compute the MTAi and derived methods is quick and easy. RESULTS indicate very good intrarater Intraclass Correlation Coefficient (ICC) for the MTAi, good intrarater ICC for the 2D-MTA, yrMTA and yrRMTA and also good interrater ICC for the MTAi, 2D-MTA, yrMTA and yrRMTA.
CONCLUSION: Our data support that MTAi and derived methods (2D-MTA, yrMTA and yrRTMA) have good to very good intrarater and interrater reproducibility and may be easily implemented in clinical practice even if new users have no experience tracing the area of regions of interest.

Entities:  

Keywords:  2D-MTA; MTAi; feasibility; planimetry; reproducibility; yrMTA; yrRMTA

Year:  2014        PMID: 25414666      PMCID: PMC4220710          DOI: 10.3389/fnagi.2014.00305

Source DB:  PubMed          Journal:  Front Aging Neurosci        ISSN: 1663-4365            Impact factor:   5.750


Introduction

The recent focus on biomarkers in the diagnosis of Alzheimer’s disease (AD) have created a need to translate research findings into tools for use in everyday clinical practice. Although AD and mild cognitive impairment (MCI) are commonly diagnosed using criteria based in clinical findings, MRI findings may aid the clinical diagnosis, and may predict clinical progression. New research criteria have recently been proposed for AD, and MCI that incorporate (disproportionate) medial temporal lobe (MTL) or hippocampal atrophy on MRI as one of the supportive features. Age-associated differences are detected in the MTL with an acceleration of Medial Temporal Lobe Atrophy (MTA) starting around 72 years of age in healthy people (Jack et al., 2004; Salk et al., 2014). However, these changes are modest and their rate of progression over time is relatively slow with a mean rate of about 1.6% per year. Accelerated MTA is a consistent finding in AD and MCI with rates of about 2.8% in stable MCI, 3.7% in MCI transitioning to AD (MCI progressors), and up to 4.0% in AD. Frontotemporal dementia may also lead to MTA, but in a different pattern: behavioral frontotemporal dementia and semantic dementia show atrophy in the anterior portion of the hippocampus, and in semantic dementia the atrophy is asymmetrical, with the left hippocampus being affected more severely. No significant hippocampal atrophy is detected in non-fluent progressive aphasia (Mesulam et al., 2014). Other diseases such as dementia with Lewy bodies do not show MTA or it is much milder (Menéndez-González et al., 2014). All these changes can be measured on brain MRI using different approaches on structural MRI. Volumetric techniques quantify the volume of regions of interest on ad-hoc MRI studies that are quantified by using well manual well automatic image analysis. Planimetry methods are conceived to be used on standard MRI studies in routine clinical practice by measuring the area of regions of interest manually. Linear methods use measures of the width or height of brain structures, including the ventricular system or spaces around the brain cortex. Visual assessment rating scales are a quick way of assessing atrophy of the MTL on one single coronal MRI slice straightforward, and can be performed easily in the clinical setting; the disadvantage is that these scales are totally subjective and there is a loss of accuracy compared with objective analysis (Scheltens et al., 1992). In contrast to MTA, ventricular enlargement in old people lacks specificity, representing a measure of global brain atrophy and is strongly associated with aging both in healthy and diseased people. In addition, almost any neurodegenerative disorder affecting the brain hemispheres leads to some degree of ventricular enlargement, and so do some psychiatric conditions. Thus, it is interesting to compare measures indicative of atrophy in the MTL with measures indicative of global brain atrophy. This can be done using volumetry (3D) or planimetry (2D). Shortly, the “Medial Temporal-lobe Atrophy index” (MTAi), is a simple method for measuring the relative extent of atrophy in the MTL in relation to the global brain atrophy (Menéndez-González, 2014b). This 2D-method consists on calculating a ratio using the area of three regions traced manually on one single coronal MRI slide. High values are suggestive of atrophy in the MTL out of proportion to other brain structures, and therefore the pattern of atrophy matches the expected in typical AD (Galton et al., 2001; van de Pol et al., 2006). Albeit preliminary studies showed interest of planimetric methods for diagnosing AD, frontotemporal lobe degeneration (FTLD) and cognitive impairment in Parkinson’s disease (PD), formal feasibility and validity studies remained pending. As a first step, we aimed to assess the feasibility of the MTAi and derived methods: 2D-Medial Temporal Atrophy (2D-MTA), yearly rate of MTA (yrRMTA) and tyearly rate of relative MTA (yrRMTA). Mainly, we aimed to assess the reproducibility of measuring the areas needed to compute these indices. Reproducibility refers to the degree of agreement between measurements or observations conducted on replicate specimens by different people, as part of the precision of a test method. Test–retest variability can be caused by intra-individual variability and intra-observer variability. These parameters have paramount importance when validating a new diagnostic test (Bossuyt et al., 2003); and some recommendations on the validation of biomarkers for diagnosing dementias have also remarked the importance of assessing them in first term (McGhee et al., 2014; Noel-Storr et al., 2014). We also aimed to assess the efforts needed to start using these methods correctly.

Methods

A series of 230 1.5T-MRI studies of subjects ranging 65–85 years old who had been studied for cognitive impairment were used in this study. Six inexperienced tracers (IT) plus one experienced tracer (ET) took part in this study. IT had different backgrounds in life sciences, basic neuroanatomical knowledge, and no previous experience in tracing areas of brain regions at all. The ET is one of the researchers who described the methods and has extensive experience using them. First, the IT read the protocol of the MTAi (Menéndez-González, 2014a). They were in charge of installing the DICOM software, loading MRI studies, selecting the appropriate slide and tracing the three areas needed to compute the MTAi on each hemisphere (right and left A, B and C) according to the original protocol, on a number of MRI studies ranging from 20 to 120 cases. The IT used different DICOM viewers depending on the operating system installed in their computers: 3 IOS users used Osirix™ and 3 Windows users used ONIS™. The areas traced by the IT were corrected by the ET in all cases. The MTAi consists on calculating a ratio using the area of three regions traced manually on one single coronal MRI slide at the level of the interpeduncular fossa: (1) the MTL region (A), defined in a coronal brain slide as the four-sided space bordered in its inferior side by the tentorium cerebelli, in its medial side by the cerebral peduncles, in its upper side by the roof of the temporal horn of the lateral ventricle and in its lateral side by the collateral sulcus and a straight-line linking the collateral sulcus with the lateral edge of the temporal horn of the lateral ventricle; (2) the parenchima within the medial temporal region, that includes the hippocampus and the parahippocampal gyrus—the fimbria taenia and plexus choroideus are excluded—(B); and (3) the body of the ipsilateral lateral ventricle (C) (Figure 1). Therefrom we can compute the “2D-Medial Temporal Atrophy” (2D-MTA = A−B) that represents absolute atrophy of the MTL; and the ratio “Medial Temporal Atrophy index” (MTAi = (A−B) × 10/C) that represents the relative atrophy of the MTL in comparison with the enlargement of the lateral ventricles, that represent global brain atrophy. The MTAi is suitable to assess the asymmetry of relative MTA within a subject. High asymmetry is typical of some types of FTLD. However, as there is important inter-individual variability in the size of the lateral ventricles, this index is not recommended for comparing subjects but to track the progression in a given subject over time. Indeed, if we have 2 MRI studies from different times (1 = first one, 2 = second one), we can also compute the yrMTA as follows: yrMTA = (A2−B2)−(A1−B1) × 1200/(#months between MRI studies) and the yearly rate of relative MTA (yrRMTA) as follows: yrRMTA=(A2−B2)−(A1−B1) × 1200/(C2−C1) × (# months between MRI studies).
Figure 1

MRI coronal section passing through the interpeduncular fosae. The boundaries of the three areas needed for calculating the Medial Temporal Atrophy index (MTAi) and derived methods have been drawn in three different colors: (1) the medial temporal lobe region (A, red), defined in a coronal brain slide as the space bordered in its inferior side by the tentorium cerebelli, in its medial side by the cerebral peduncles, in its upper side by the roof of the temporal horn of the lateral ventricle and in its lateral side by the colateral sulcus and a straight-line linking the colateral sulcus with the lateral edge of the temporal horn of the lateral ventricle; (2) the parenchima within the medial temporal region, that includes the hippocampus and the parahippocampal girus (B, blue); and (3) the body of the ipsilateral lateral ventricle (C, green).

MRI coronal section passing through the interpeduncular fosae. The boundaries of the three areas needed for calculating the Medial Temporal Atrophy index (MTAi) and derived methods have been drawn in three different colors: (1) the medial temporal lobe region (A, red), defined in a coronal brain slide as the space bordered in its inferior side by the tentorium cerebelli, in its medial side by the cerebral peduncles, in its upper side by the roof of the temporal horn of the lateral ventricle and in its lateral side by the colateral sulcus and a straight-line linking the colateral sulcus with the lateral edge of the temporal horn of the lateral ventricle; (2) the parenchima within the medial temporal region, that includes the hippocampus and the parahippocampal girus (B, blue); and (3) the body of the ipsilateral lateral ventricle (C, green). Finally, tracers underwent a short survey on their experience learning to compute the MTAi and experience of usage, including items relative to training time needed to understand and apply the MTAi (number of attempts needed until the ET verified the tracing was correct), time needed to perform a study after training (timed by the own tracers, in minutes) and overall satisfaction (measured using a simple qualitative scale: easy/normal/hard). Statistical analyses were performed with the softwares R™ and Epidat™. Computation of the MTA, 2D-MTA, yrMTA and yrRMTA were made following the formulas explained above (Menéndez-González et al., 2014). The reproducibility was assessed using the Intraclass Correlation Coefficient (ICC)-Model 2, one by one for every of the three areas needed to compute the MTAi on each hemisphere and for the final MTAi results (right and left). We used a qualitative scale to qualify the strength of concordance as very good (>0.90), good (0.80–0.90), moderate (0.60–0.80) and poor (<0.60).

Results

Reproducibility: results from the test-retest studies

In total, IT traced areas from 290 MRI studies from 230 cases, 60 of which also had a 1-year follow-up MRI study. Ninety studies were traced twice by the same IT (180 sets of results), and 200 were traced twice by 2 different IT (400 sets of results). We used the set of 180 double-traced by same-tracer results to assess the intrarater reproducibility and the set of 400 double-traced by different-tracer results to assess the interrater reproducibility. Thirty cases of the each set corresponded to the 1 year follow-up MRI. Thus, we computed the yrMTA and the yrRMTA in 60 cases and the MTAi and 2D-MTA in 230 cases. Results of intrarater and interrater reproducibility are shown in Tables 1, 2 respectively.
Table 1

Intrarater Intraclass Correlation Coefficient and strength of concordance among the different areas needed to compute the MTAi, 2D-MTA, yrMTA and yrRMTA.

CCICI 95%Strength
MeanInferiorSuperior
rA0.870.680.91Good
lA0.860.660.90Good
rB0.830.710.89Good
lB0.840.760.87Good
rC0.950.920.94Very good
lC0.940.910.96Very good
rMTAi0.910.900.92Very good
lMTAi0.920.910.93Very good
r2D-MTA0.880.800.95Good
l2D-MTA0.850.810.89Good
ryrMTA0.820.760.89Good
lyrMTA0.840.770.90Good
ryrRMTA0.810.770.87Good
lyrRMTA0.830.750.89Good

r: right hemisphere; l: left hemisphere.

Table 2

Interrater Intraclass Correlation Coefficient and strength of concordance among the different areas needed to compute the MTAi, 2D-MTA, yrMTA and yrRMTA.

CCICI 95%Strength
MeanInferiorSuperior
rA0.870.690.92Good
lA0.860.720.91Good
rB0.830.690.89Good
lB0.840.710.89Good
rC0.880.730.91Very good
lC0.900.870.92Very good
rMTAi0.880.820.92Good
lMTAi0.870.830.91Good
r2D-MTA0.840.790.90Good
l2D-MTA0.850.810.91Good
ryrMTA0.830.740.89Good
lyrMTA0.830.750.90Good
ryrRMTA0.820.750.88Good
lyrRMTA0.810.760.86Good

r: right hemisphere; l: left hemisphere.

Intrarater Intraclass Correlation Coefficient and strength of concordance among the different areas needed to compute the MTAi, 2D-MTA, yrMTA and yrRMTA. r: right hemisphere; l: left hemisphere. Interrater Intraclass Correlation Coefficient and strength of concordance among the different areas needed to compute the MTAi, 2D-MTA, yrMTA and yrRMTA. r: right hemisphere; l: left hemisphere.

Satisfaction: results from the survey

IT needed to train with 2–5 cases (mean 3 cases) before being able to compute the MTAi on their own correctly. After training, IT needed between 4 and 7 min (mean 5 min) to examine a new case. All tracers rated the method as “easy to learn” and “easy to apply”.

Discussion

One of the strengths of planimetry methods is that can be measured using almost any of the DICOM softwares commonly used by clinicians or radiologists to visualize medical images worldwide. Most of these softwares are intuitive and require little or no training at all. Learning to trace the areas needed to compute the MTAi and derived methods is quick and easy even for naive tracers. Even more importantly, tracing these areas have good intra- and interrater reproducibility. As expected, the area with the best intra- and interrater ICC was area C—the lateral ventricle—since it has the easiest anatomical limits. Areas A and B had poorer intrarater and interrater ICC since anatomical limits are somewhat more complicated. However, the intrarater and interrater ICC for areas A and B is still good enough to yield very good intrarater ICC for the MTAi, good intrarater ICC for the 2D-MTA, yrMTA and yrRMTA and also good interrater ICC for the MTAi, 2D-MTA, yrMTA and yrRMTA. These results are comparable to those from automatic volumetry (Hsu et al., 2002; Wolz et al., 2014) and much better than those from manual volumetry and visual scales (Scheltens et al., 1997; Hsu et al., 2002). Particularly, assessment of cerebral atrophy using visual rating scales is totally subjective and has moderate intrarater and poor interrater reproducibility (Scheltens et al., 1997). Accurate manual volumetric assessment requires standard operating procedures that include the know-how specific for the modality, acquisition parameters, and extensive learning and ad-hoc softwares that also require training to be used correctly (Frisoni et al., 2014). In addition, harmonization of manually segmented hippocampus is still in progress (Frisoni and Jack, 2011). Thus, manual volumetric methods have a steep learning curve while the MTAi while derived 2D methods have a learning curve with a quick start. The MTAi and derived methods may be easily implemented for estimating MTA in clinical practice, even if new users have no experience tracing the area of regions of interest. Indeed, any health professional with basic neuroanatomical knowledge can take these measures after short training. The MTAi and derived methods can also readily be incorporated into a standardized radiological report and may also be useful in clinical trials.

Conclusions

In conclusion, results from this feasibility study support that the MTAi and derived methods (2D-MTA, yrMTA and yrRMTA) have good to very good intrarater and interrater reproducibility and may be easily implemented for estimating MTA in clinical practice, even if new users have no experience tracing the area of regions of interest.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
  15 in total

1.  The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration.

Authors:  Patrick M Bossuyt; Johannes B Reitsma; David E Bruns; Constantine A Gatsonis; Paul P Glasziou; Les M Irwig; David Moher; Drummond Rennie; Henrica C W de Vet; Jeroen G Lijmer
Journal:  Ann Intern Med       Date:  2003-01-07       Impact factor: 25.391

2.  Hippocampal atrophy on MRI in frontotemporal lobar degeneration and Alzheimer's disease.

Authors:  L A van de Pol; A Hensel; W M van der Flier; P-J Visser; Y A L Pijnenburg; F Barkhof; H Josef Gertz; P Scheltens
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-11-23       Impact factor: 10.154

3.  An MRI study of age-related changes in the dimensions related temporal lobe.

Authors:  Ismail Salk; Mehmet Haydar Atalar; Ferhat Sezer; Hulusi Egilmez; Ali Cetin; Mubeccel Arslan
Journal:  Int J Clin Exp Med       Date:  2014-03-15

4.  The EADC-ADNI Harmonized Protocol for manual hippocampal segmentation on magnetic resonance: evidence of validity.

Authors:  Giovanni B Frisoni; Clifford R Jack; Martina Bocchetta; Corinna Bauer; Kristian S Frederiksen; Yawu Liu; Gregory Preboske; Tim Swihart; Melanie Blair; Enrica Cavedo; Michel J Grothe; Mariangela Lanfredi; Oliver Martinez; Masami Nishikawa; Marileen Portegies; Travis Stoub; Chadwich Ward; Liana G Apostolova; Rossana Ganzola; Dominik Wolf; Frederik Barkhof; George Bartzokis; Charles DeCarli; John G Csernansky; Leyla deToledo-Morrell; Mirjam I Geerlings; Jeffrey Kaye; Ronald J Killiany; Stephane Lehéricy; Hiroshi Matsuda; John O'Brien; Lisa C Silbert; Philip Scheltens; Hilkka Soininen; Stefan Teipel; Gunhild Waldemar; Andreas Fellgiebel; Josephine Barnes; Michael Firbank; Lotte Gerritsen; Wouter Henneman; Nikolai Malykhin; Jens C Pruessner; Lei Wang; Craig Watson; Henrike Wolf; Mony deLeon; Johannes Pantel; Clarissa Ferrari; Paolo Bosco; Patrizio Pasqualetti; Simon Duchesne; Henri Duvernoy; Marina Boccardi
Journal:  Alzheimers Dement       Date:  2014-09-27       Impact factor: 21.566

5.  Temporal lobe rating scale: application to Alzheimer's disease and frontotemporal dementia.

Authors:  C J Galton; B Gomez-Anson; N Antoun; P Scheltens; K Patterson; M Graves; B J Sahakian; J R Hodges
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-02       Impact factor: 10.154

6.  Comparison of automated and manual MRI volumetry of hippocampus in normal aging and dementia.

Authors:  Yuan-Yu Hsu; Norbert Schuff; An-Tao Du; Kevin Mark; Xiaoping Zhu; Dawn Hardin; Michael W Weiner
Journal:  J Magn Reson Imaging       Date:  2002-09       Impact factor: 4.813

7.  Asymmetry and heterogeneity of Alzheimer's and frontotemporal pathology in primary progressive aphasia.

Authors:  M-Marsel Mesulam; Sandra Weintraub; Emily J Rogalski; Christina Wieneke; Changiz Geula; Eileen H Bigio
Journal:  Brain       Date:  2014-02-25       Impact factor: 13.501

8.  Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates.

Authors:  P Scheltens; D Leys; F Barkhof; D Huglo; H C Weinstein; P Vermersch; M Kuiper; M Steinling; E C Wolters; J Valk
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-10       Impact factor: 10.154

9.  MTA index: a simple 2D-method for assessing atrophy of the medial temporal lobe using clinically available neuroimaging.

Authors:  Manuel Menéndez-González; Alfonso López-Muñiz; José A Vega; José M Salas-Pacheco; Oscar Arias-Carrión
Journal:  Front Aging Neurosci       Date:  2014-03-24       Impact factor: 5.750

Review 10.  A systematic review of biomarkers for disease progression in Alzheimer's disease.

Authors:  David J M McGhee; Craig W Ritchie; Paul A Thompson; David E Wright; John P Zajicek; Carl E Counsell
Journal:  PLoS One       Date:  2014-02-18       Impact factor: 3.240

View more
  5 in total

Review 1.  Unexpected (123I)FP-CIT SPECT findings: SWIDD, SWEDD and all DAT.

Authors:  Balestrino Roberta; Barone Paolo; Filippi Massimo; Erro Roberto
Journal:  J Neurol       Date:  2021-09-18       Impact factor: 6.682

2.  Indices of Regional Brain Atrophy: Formulae and Nomenclature.

Authors:  Manuel Menendez; Oscar Arias-Carrión
Journal:  Cureus       Date:  2015-08-06

3.  Manual Planimetry of the Medial Temporal Lobe Versus Automated Volumetry of the Hippocampus in the Diagnosis of Alzheimer's Disease.

Authors:  Manuel Menéndez González; Esther Suárez-Sanmartin; Ciara García; Pablo Martínez-Camblor; Eric Westman; Andy Simmons
Journal:  Cureus       Date:  2016-03-26

4.  A new age-related cutoff of medial temporal atrophy scale on MRI improving the diagnostic accuracy of neurodegeneration due to Alzheimer's disease in a Chinese population.

Authors:  Mingqing Wei; Jing Shi; Jingnian Ni; Xuekai Zhang; Ting Li; Zilong Chen; Mengling Zhou; Liping Zhang; Zhongjian Tan; Yongyan Wang; Jinzhou Tian
Journal:  BMC Geriatr       Date:  2019-02-28       Impact factor: 3.921

Review 5.  Imaging Biomarkers in Alzheimer's Disease: A Practical Guide for Clinicians.

Authors:  Nasim Sheikh-Bahaei; Seyed Ahmad Sajjadi; Roido Manavaki; Jonathan Harvey Gillard
Journal:  J Alzheimers Dis Rep       Date:  2017-07-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.